Xander Guarna
My identify is Xander Guarna from the Jefferies Healthcare Funding Banking crew, and it is my pleasure to introduce Faraz Ali from Tenaya Therapeutics.
Faraz Ali
CEO, Interim Principal Monetary Officer & Director
Thanks, and because of the Jefferies crew for inviting us and giving us this chance to let you know slightly bit extra about Tenaya Therapeutics. We’re a publicly traded firm. These are forward-looking statements. Our goal is to remodel and lengthen the lives of sufferers by way of the invention, improvement and supply of doubtless healing therapies that concentrate on the underlying causes of coronary heart illness.
There are a few issues that make Tenaya distinctive. One, the distinctive give attention to coronary heart illness; two, we go after each uncommon and prevalent types of coronary heart illness; and three, that we truly are modality agnostic. And so we pursue gene remedy, small molecules, cardiac regeneration, gene modifying, we actually comply with the science, and people are among the issues that set us aside. We have now 3 thrilling medical stage applications. And within the time I have been allotted right this moment, I will not be capable to do justice to all of them. However most significantly, we have now near-term catalysts within the type of readouts from our 2 gene remedy applications and together with the potential for regulatory alignment on pivotal research. So an thrilling time for the corporate.
And actually, that’s the speedy alternative for the corporate proper now. The two gene remedy applications are TN-201 and TN-401, and people are shifting relentlessly in the direction of pivotal research. Each are engaging as a result of they deal with massive alternatives. You’ll be able to see 120,000 sufferers and 75,000 sufferers in
